Crinetics Pharmaceuticals, Inc.
CRNXCrinetics Pharmaceuticals is a global pharmaceutical company known for developing drugs for the treatment of endocrine-related diseases. It was founded by Scott Struthers, Frank Zhu, Ana Kusnetzow, and Stephen F. Betz in 2008 and is headquartered in San Diego, California. It went public on NASDAQ in 2018.
Drugs in Pipeline
5
Phase 3 Programs
2
Upcoming Catalysts
4
Next Catalyst
Feb 28, 2026
20dMarket Overview
Stock performance and market intelligence
4 upcoming, 0 past
FDA PDUFA Date paltusotine (standard)
For acromegaly. NDA filing. Extracted from SEC filing: 8-K
SourceFDA PDUFA Date paltusotine (standard)
For acromegaly. NDA filing. Extracted from SEC filing: 8-K
SourceFDA PDUFA Date paltusotine (standard)
For acromegaly. NDA filing. Extracted from SEC filing: 8-K
Sourceatumelnant Phase 2 Results Expected
Primary completion for atumelnant trial (NCT05804669) in Cushing Syndrome
SourceAI Predictions & Institutional Flow
Machine learning insights and smart money movement
FDA Submissions
Pending NDA/BLA submissions with predicted PDUFA dates
Drug Pipeline
Clinical development programs and drug candidates
Paltusotine
Acromegaly
Atumelnant
Congenital Adrenal Hyperplasia
atumelnant (CRN04894)
Congenital Adrenal Hyperplasia
Randomized: 40 mg Paltusotine
Carcinoid Syndrome
CRN09682
SST2-positive Neuroendocrine Neoplasms
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
Paltusotine | Phase 3 | Acromegaly | - |
Atumelnant | Phase 3 | Congenital Adrenal Hyperplasia | - |
atumelnant (CRN04894) | Phase 2 | Congenital Adrenal Hyperplasia | - |
Randomized: 40 mg Paltusotine | Phase 2 | Carcinoid Syndrome | - |
CRN09682 | Phase 2 | SST2-positive Neuroendocrine Neoplasms | - |
Regulatory & News
Approvals, filings, and latest developments